Peill · Journal of psychopharmacology (Oxford, England) 2022 · psychometric validation and prospective observational cohort study · n=1165

Validation of the Psychological Insight Scale: A new scale to assess psychological insight following a psychedelic experience.

Cited 139 times in the scientific literature.

Level 3 - non-randomized controlled study

Prospective observational cohort and cross-sectional validation survey

PubMed 34983255 · doi:10.1177/02698811211066709 · record verified 2026-08-28

What was done

Researchers developed and validated the Psychological Insight Scale (PIS), a 6- to 7-item instrument assessing post-acute psychological insight (PIS-6) and accompanying behavioral changes (item 7) following a psychedelic experience. Psychometric properties were tested prospectively in 886 individuals undergoing a planned psychedelic experience and validated in an independent cross-sectional cohort of 279 participants from a global survey. Analyses included principal components analysis, longitudinal internal consistency testing, convergent validity assessment against the Therapeutic-Realizations Scale, criterion validation, and mediation modeling linking emotional breakthrough to long-term well-being.

What was found

Principal components analysis revealed a primary component explaining 73.57% of the variance, with an average Cronbach's α of 0.94 across multiple timepoints. Criterion validity and convergent validity were confirmed. PIS scores significantly mediated the relationship between acute emotional breakthrough and long-term well-being, though exact mediation effect sizes and confidence intervals were not reported in the abstract.

Why it matters

The PIS provides a brief, validated tool to measure post-acute psychological insight rather than just acute subjective effects. It demonstrates that psychological insight functions as a mediator connecting acute psychedelic experiences to sustained improvements in well-being.

Limits

Findings are based on self-selected naturalistic survey participants rather than a randomized or controlled clinical trial. The abstract reports no numerical effect sizes or confidence intervals for the mediation analysis, nor details regarding drug identity, dose, or setting.

Cited by